A Retrospective Study on the Onset of Menopause after Chemotherapy: Analysis of Data Extracted from the Jean Perrin Comprehensive Cancer Center Database Concerning 345 Young Breast Cancer Patients Diagnosed between 1994 and 2012

被引:7
|
作者
Dohou, Joyce [1 ,2 ,3 ]
Mouret-Reynier, Marie-Ange [1 ,2 ]
Kwiatkowski, Fabrice [4 ,8 ]
Arbre, Marie [4 ]
Herviou, Pauline [2 ,5 ,6 ]
Pouget, Melanie [2 ,5 ,7 ]
Abrial, Catherine [1 ,2 ,3 ]
Penault-Llorca, Frederique [1 ,2 ,3 ]
机构
[1] Univ Auvergne, ERTICA EA 4677, Clermont Ferrand, France
[2] Ctr Jean Perrin, 58 Rue Montalembert, FR-63011 Clermont Ferrand, France
[3] CIC, Clermont Ferrand, France
[4] Ctr Jean Perrin, Lab Oncol Mol, Clermont Ferrand, France
[5] Univ Auvergne, Clermont Ferrand, France
[6] CHU Clermont Ferrand, Serv Pharmacol Med, INSERM U1107, NEURO DOL, Clermont Ferrand, France
[7] UMR 990 INSERM UdA, Clermont Ferrand, France
[8] Univ Blaise Pascal Aubiere, UMR CNRS 6620, Lab Math, Aubiere, France
关键词
Breast cancer; Premature ovarian insufficiency; Chemotherapy; Premenopausal women; INDUCED AMENORRHEA; NATURAL MENOPAUSE; PREMENOPAUSAL WOMEN; MENSTRUAL HISTORY; OVARIAN-FUNCTION; AGE; IMPACT; METAANALYSIS; SUPPRESSION; MANAGEMENT;
D O I
10.1159/000455049
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: Young breast cancer (BC) patients receiving chemotherapy are at risk of chemotherapy-induced menopause (CIM). We sought to define the incidence rate of premature menopause after chemotherapy and to retrospectively investigate factors related to the onset of menopause. Methods: We identified BC patients who had received chemotherapy at the Cancer Center (Centre Jean-Perrin). We selected premenopausal women aged between 18 and 50 years at the moment of diagnosis who received chemotherapy between 1994 and 2012. Results: Of the 345 selected patients, the median age was 42 years (interquartile range: 38-46). CIM was defined as amenorrhea for at least 2 years following the end of chemotherapy. A total of 260 premenopausal women versus 85 menopausal women were included. Among the 85 menopausal women, only 46 were in the CIM group (13.3%). This rate increased in the group of women aged >43 years at diagnosis and with early hot flushes. Conclusion: CIM occurred in 13.3% of BC patients after chemotherapy. Age >43 years and early hot flushes were significantly associated with the risk of CIM. We suggest that the definition of CIM should be standardized in the literature: "amenorrhea of at least 2 years" seems a good cutoff, although 2 patients recovered their menstrual cycles beyond this limit. (C) 2017 S. Karger AG, Basel
引用
收藏
页码:255 / 263
页数:9
相关论文
共 8 条
  • [1] Impact of obesity on pathological complete remission in early stage breast cancer patients after neoadjuvant chemotherapy: a retrospective study from a German University breast center
    Englisch, Johannes Felix
    Englisch, Alexander
    Dannehl, Dominik
    Eissler, Kenneth
    Tegeler, Christian Martin
    Matovina, Sabine
    Volmer, Lea Louise
    Wallwiener, Diethelm
    Brucker, Sara Y.
    Hartkopf, Andreas
    Engler, Tobias
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2025, 311 (02) : 437 - 442
  • [2] Trends in BRCA testing among patients diagnosed with breast cancer -a retrospective analysis of a United States commercial claims database from the PRIOR-1 study
    Corman, Shelby
    Kale, Hrishikesh
    Shah, Pooja
    Adeboyeje, Gboyega
    CANCER RESEARCH, 2021, 81 (04)
  • [3] Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trials
    Sibylle Loibl
    Christian Jackisch
    Bianca Lederer
    Michael Untch
    Stefan Paepke
    Sherko Kümmel
    Andreas Schneeweiss
    Jens Huober
    Jörn Hilfrich
    Claus Hanusch
    Bernd Gerber
    Holger Eidtmann
    Carsten Denkert
    Serban Dan Costa
    Jens-Uwe Blohmer
    Valentina Nekljudova
    Keyur Mehta
    Gunter von Minckwitz
    Breast Cancer Research and Treatment, 2015, 152 : 377 - 387
  • [4] Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trials
    Loibl, Sibylle
    Jackisch, Christian
    Lederer, Bianca
    Untch, Michael
    Paepke, Stefan
    Kuemmel, Sherko
    Schneeweiss, Andreas
    Huober, Jens
    Hilfrich, Joern
    Hanusch, Claus
    Gerber, Bernd
    Eidtmann, Holger
    Denkert, Carsten
    Costa, Serban Dan
    Blohmer, Jens-Uwe
    Nekljudova, Valentina
    Mehta, Keyur
    von Minckwitz, Gunter
    BREAST CANCER RESEARCH AND TREATMENT, 2015, 152 (02) : 377 - 387
  • [5] Onset of MRONJ in Breast Cancer Patients after Switching from Low to High Dose of Bone Modifying Agents Due to Bone Metastases Development: A Single Center Retrospective Cohort Study
    Mauceri, Rodolfo
    Coppini, Martina
    Campisi, Giuseppina
    ORAL, 2022, 2 (04): : 274 - 285
  • [6] The risk of amenorrhoea after adjuvant chemotherapy for early stage breast cancer is related to inter-individual variations in chemotherapy-induced leukocyte nadir in young patients: Data from the randomised SBG 2000-1 study
    Rosendahl, Mikkel
    Ahlgren, Johan
    Andersen, Jorn
    Bergh, Jonas
    Blomquist, Carl
    Lidbrink, Elisabet
    Lindman, Henrik
    Mouridsen, Henning
    Bjerre, Karsten
    Andersson, Michael
    EUROPEAN JOURNAL OF CANCER, 2009, 45 (18) : 3198 - 3204
  • [7] This study evaluates the impact of metabolic syndrome on pathological response in young patients (≤45 years) with HER2-neu negative breast cancer after preoperative chemotherapy. The study includes the analysis of pathologic data to determine the relationship between metabolic status and treatment efficacy
    Martyniuk, O.
    Tarasenko, T.
    Chekhun, V.
    Smolanka, I.
    Bondar, M.
    Shudrak, P.
    EUROPEAN JOURNAL OF CANCER, 2024, 200 : 49 - 49
  • [8] Estimating the effects of patient-reported outcome (PRO) diarrhea and pain measures on PRO fatigue: Data analysis from a phase II study of abemaciclib monotherapy, a CDK4 and CDK6 inhibitor, in patients with HR+/HER2-breast cancer after chemotherapy for metastatic disease-MONARCH 1.
    Boye, Mark
    Houghton, Katherine
    Stull, Donald E.
    Ainsworth, Claire
    Price, Gregory L.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35